Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Press Release Policy Restricts Free Speech, Needs Revision – PhRMA

Sep 23 2002

• By The Pink Sheet

Related Content

Lilly Evista Overstatement of Benefits Cited By FDA For A Second Time

Jan 25 1999

FDA Seeks Comment On Ad Regs: Can Rx Be More Regulated Than OTCs?

May 20 2002

Merck Vioxx Warning Letter Could Be Incentive For Large Cardio Safety Study

Oct 01 2001

FDA Drug Name Policy "Discourages" New Brand Names For Old Ingredients

Apr 23 2001

CBER/CDER Consolidation Working Group Set To Meet Week Of Sept. 16

Sep 09 2002

Amgen Ends Praecis Plenaxis Collaboration After FDA Requests More Studies

Sep 24 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window